Accordingly, a senolytic therapy with ablation of senescent fibroblasts and, in consequence, their secretory phenotype, preventing CREB activation, may effectively complement conventional therapies for melanoma and other tumor entities in elderly patients. Here, CREB1 is linked to melanoma.